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Klotho is an anti-aging protein predominantly expressed in
the kidney, parathyroid glands, and choroid plexus of the
brain. It is a single-pass transmembrane protein with a large
extracellular domain. The extracellular domain of Klotho is
cleaved and released into extracellular fluid, including blood,
urine, and cerebrospinal fluid. The membrane-bound full-
length Klotho and secreted extracellular domain of Klotho
have distinct functions. Membrane Klotho interacts with
fibroblast growth factor (FGF) receptors to form high-affinity
receptors for FGF23. Secreted Klotho functions as a humoral
factor that regulates several ion channels and transporters,
and other processes, including insulin and insulin-like growth
factor signaling. This mini-review focuses on the mechanisms
of regulation of cell-surface abundance of ion channels by
secreted Klotho and the importance of these effects of Klotho
in physiology and pathological conditions.
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Klotho is type-1 transmembrane protein predominantly
expressed in the kidney, parathyroid glands, and the epithelial
cells of choroid plexus of the brain.1 Mice with disruption in
the Klotho gene display multiple phenotypes closely resem-
bling human aging, including shortened lifespan, muscle and
skin atrophy, pulmonary emphysema, osteopenia, infertility,
hyperphosphatemia, and vascular and soft tissue calcifica-
tion.1 In support of its function in aging suppression,
overexpression of Klotho in mice extends their lifespan.2
The Klotho gene, in mice and humans as well, contains
5 exons and encodes a single-pass transmembrane polypep-
tide of 1012 amino acids (for human Klotho; 1014 amino
acids for mouse Klotho).1 The majority of amino acids in the
Klotho peptide (B980 residues) reside in the amino-terminal
extracellular domain, which is followed by 21 amino acids
membrane-spanning domain, and a 11 amino acid short
intracellular carboxyl terminus (Figure 1a).1 The extracellular
domain consists of two internal repeat sequences of 440
amino acids, named KL1 and KL2, respectively.1,3 The linker
region between the two internal repeats contains a stretch of
four basic amino acids (Lys-Lys-Arg-Lys) that forms a
potential site for proteolytic cleavage. A secreted form of
Klotho consisting of the full-length extracellular domain is
detected in the blood, urine, and cerebrospinal fluid (Figure
1b).2,4 Recently, Chen et al.5 reported that the extracellular
domain is cleaved by the metalloproteases ADAM10 and
ADAM17 and that insulin stimulates the cleavage of Klotho.
Both human and mouse Klotho gene are alternatively
spliced.6 Besides the transcript that encodes the full-length
Klotho of 1012-1014 amino acids, an alternatively spliced
form of Klotho mRNA encoding the KL1 repeat of Klotho is
detected in humans and mice.6 Imura et al.4 reported the
existence of the entire extracellular domain of Klotho, but not
KL1 or KL2 fragment, in serum and cerebrospinal fluid. KL1
and KL2 fragments, however, can be detected in the mouse
and human urine (Kuro-o M, personal communication). The
existence of KL1 and KL2 fragments in the urine is likely a
result of cleavage of the full-length extracellular domain at
the linker region by proteases. However, the possibility that
the alternatively spliced KL1 transcript produces a peptide,
which is secreted into urine, cannot be excluded.
The KL1 and KL2 repeats each share amino-acid sequence
homology to family 1 glycosidases.1,3 Members of family 1
glycosidases contain two highly conserved glutamate residues
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critical for the enzymatic activity.3,7 One of these acts as a
nucleophile, the other as an acid-base catalyst. In Klotho, the
two glutamate residues, however, are replaced by an
asparagine at the acid-base catalyst position in the KL1
repeat and an alanine or a serine at the nucleophile position
in the KL2 repeat, respectively.
Since the recognition of homology to family 1 glycosi-
dases, much effort has been devoted to investigate whether
Klotho has enzymatic glycosidase activity. Tohyama et al.8
first showed that secreted Klotho exhibits weak enzymatic
activity toward b-glucuronic acids (hydrolyzing glycosidic
bond at 73 pmol/h/mg for Klotho vs 1940 pmol/h/mg for
purified liver b-glucuronidase). They suggested that secreted
Klotho is a novel b-glucuronidase that catalyzes glucuronyla-
tion of circulating steroids or related substances to increase
their water solubility, thus enhancing their clearance by the
kidney. Recent reports suggest that secreted Klotho also
exhibits a sialidase activity and by which regulates cell-surface
expression of TRPV5 and ROMK channels (see below).9,10
REGULATION OF TRPV5 CHANNEL BY SECRETED KLOTHO
Secreted Klotho increases cell-surface abundance of TRPV5
by removing terminal sialic acids from its N-glycan
The regulation of the epithelial Ca2þ channel TRPV5 by
secreted Klotho was first reported by Chang et al.11 They
showed that treatment with secreted Klotho increases cell-
surface abundance of TRPV5 expressed in human embryonic
kidney cells and that mutation of a single asparagine for
N-glycosylation prevents the effect of Klotho. This study
provides the first evidence that secreted Klotho regulates ion
channels by modifying N-glycans. On the basis of the finding
that purified bovine liver b-glucuronidase also regulates
TRPV5, Chang et al.11 suggested that the action of Klotho is
through hydrolysis of glucuronic acids from N-glycans of the
channel. Similarly, TRPV6, a channel closely related to
TRPV5 and may co-assemble with it in the distal renal
tubules, is regulated by secreted Klotho.12 Although glucuro-
nic acids may be sugar moieties of cell-membrane protein in
the form of heparin sulfate proteoglycans,13 they are
extremely uncommon moieties of N-glycan chains of
membrane glycoproteins such as TRPV5 channels.14,15
Recently, Cha et al.9 investigated the sugar substrates of
the N-glycans of TRPV5 for Klotho and provided compelling
evidence that secreted Klotho regulates TRPV5 by a sialidase,
rather than glucuronidase activity. As shown in Figure 2, the
complex type N-glycan chains of glycoproteins such as
TRPV5 are comprised of up to four branches.14,15 Each
branch is initiated by the attachment of N-acetylglucosamine
to underlying a3 or a6 mannose by b2, b4, or b6-linkage,
followed by the addition of galactose to form the disaccharide
galactose-N-acetylglucosamine or N-acetyllactosame (Lac-
NAc). Galactoses may be the terminal residues or they can be
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Figure 1 |Domain structure and topology of Klotho.
(a) Domain structure of human Klotho. Not drawn to scale. SS,
KL1, KL2, TM indicate signal sequence, first and second Klotho
repeat, and transmembrane domain, respectively. (b) Membrane
topology of Klotho. The entire extracellular domain consisting of
KL1 and KL2 repeats is cleaved by ADAM10 or ADAM17 and
released into urine, blood, or cerebrospinal fluid (CSF). In the
urine, KL1 and KL2 are also detected, likely due to cleavage at the
linker region by yet unspecified protease(s). See text for details.
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Figure 2 | Structure of the typical complex type
tetra-antennary N-glycans. See text for details.
N-acetyllactosamine (LacNAc) is the ligand for galectins. Multiple
LacNAc repeats may be present in the b6 branch (formed from
underlying a6-mannose), thereby increasing the affinity of
N-glycans for galectins. Mgat5 (also known as GnT-V), b1,6
N-acetylglucosaminyltransferase V, is responsible for synthesis of
the b6 N-acetylglucosamine linkage on the a6-mannose; Mgat4a,
b3,4 N-acetylglucosaminyltransferase IVa, is responsible for
synthesis of the b4 N-acetylglucosamine linkage on the
a3-mannose. Altered expression of these enzymes changes the
number of branches of N-glycans and the number of LacNAc they
carry, thus affecting binding of glycoprotein to galectin lattice on
the cell surface. See text for specific examples of conditions/
diseases that alter the expression of these enzymes.
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further capped by sialic acids by either a2,3- or a2,6-
glycosidic linkage.16 Enzymes responsible for synthesis of
a2,3- or a2,6-linked glycosidic bonds between galactose and
sialic acid are named a2,3- and a2,6-sialyltransferase,
respectively.17
Cha et al.9 confirmed that secreted Klotho increases cell-
surface abundance of TRPV5 in human embryonic kidney
cells by an N-glycosylation-dependent manner. However,
they found that secreted Klotho does not regulate TRPV5
expressed in Chinese hamster ovary (CHO) cells, which
do not express a2,6-sialyltransferase endogenously. Forced
expression of recombinant a2,6-sialyltransferase, but not of
a2,3-sialyltransferase, confers the regulation of TRPV5 by
secreted Klotho in CHO cells. These results showed that
secreted Klotho exhibits sialidase activity toward a2,6-, but
not a2,3-linked sialic acids. To understand the mechanism of
regulation by purified liver b-glucuronidase, Cha et al.9
showed that purified liver b-glucuronidase increases TRPV5
expressed in human embryonic kidney cells but not when it is
expressed in CHO cells. As is for the regulation by secreted
Klotho, forced expression of recombinant a2,6-sialyltransfer-
ase in CHO cells confers the increase of TRPV5 by purified
liver b-glucuronidase. Thus, the effect of purified liver
b-glucuronidase on TRPV5 is due to an off-target action
toward sialic acids.
Interestingly, both KL1 and KL2 fragments can regulate
TRPV5 independently, despite their differences in the amino-
acid sequence of the putative active sites predicted on the
basis of alignment with family 1 glycosidases.9 These results
suggest that the catalytic active site of Klotho is structurally
distinct from that of family 1 glycosidases.
Increase in cell-surface abundance of TRPV5 by binding
to galectin-1
The mechanism by which removal of sialic acids by Klotho
leads to an increase in the cell-surface abundance of TRPV5
was further elucidated by Cha et al.9 Galectins are galactose-
binding lectins present widely in metazoan tissues.18 They
have either one or two carbohydrate recognition domains
that are responsible for carbohydrate binding. So far,
15 mammalian galectins have been identified. They can be
intracellularly located or secreted into extracellular space.
Intracellularly, galectins interacts with cytoplasmic and
nuclear proteins to modulate signaling pathways. Extracellu-
larly, they can crosslink cell-surface glycoproteins that are
decorated by the suitable galactose-containing ligands.
Galectin-1 is ubiquitously expressed and binds LacNAc and
a2,3-sialylated LacNAC, but not a2,6-sialylated LacNAc.19
Cha et al.9 found that knockdown of endogenous galectin-1
in human embryonic kidney cells using small-interference
RNA prevents the increase of TRPV5 abundance by secreted
Klotho. Extracellular application of antibody against galectin-1
also prevents the effect of secreted Klotho. Furthermore,
secreted Klotho has no effect on TRPV5 when its endocytosis
is prevented by coexpression with a dominant-negative
dynamin mutant. These results indicate that removal of
a2,6-sialic acids from N-glycan chains by secreted Klotho
exposes underlying LacNAc for binding to galectin-1.
Binding of TRPV5 to galectin-1 prevents endocytosis,
leading to accumulation of the channels on the cell surface
(Figure 3).
The affinity of LacNAc monomer for galectins is typically
in the range of tens of mM.19 The interaction between galectins
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Figure 3 |Mechanism for increase of cell-surface abundance of ion channels by secreted Klotho. See text for details. LacNAc
(N-acetyllactosamine) is a ligand for galectin-1. a2,6-linked sialic acids prevent binding of LacNAc to galectin-1. Removal of sialic acids from
N-glycan of TRPV5 and ROMK channels by secreted Klotho allows LacNAc binding to galectin-1, preventing endocytosis of the channels.
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and ligands can be strengthened by the formation of
polymeric LacNAc, which frequently occurs in the b1,6-
N-acetylglucosamine branch of N-glycan chains (Figure 2).
The formation of this branch is catalyzed by the Golgi enzyme
N-acetylglucosaminyltransferase (GnT-V). Using a mutant
CHO cell line lacking GnT-V and forced expression of
recombinant GnT-V, Cha et al.9 showed that removal of sialic
acids from the b1,6-N-acetylglucosamine branch is essential
for the increase of TRPV5 by secreted Klotho. How Klotho
recognizes the b1,6-N-acetylglucosamine branch and specifi-
cally targets to sialic acids on this branch remains an enigma.
Control of resident time of glycoproteins in the cell
membrane by galectin–N-glycan interaction
Recent studies have shown that binding to extracellular
galectins by N-glycan chains is an important mechanism for
regulation of cell-surface abundance and activity of membrane
glycoproteins.14,15,20 Clustering of T-cell receptors in response
to antigen presentation, which is restricted by binding of
receptors to the extracellular galectin-3, is critical for T-cell
activation. Demetriou et al.14 reported that reduction of
LacNAc in the N-glycans of T-cell receptors caused by
mutation of GnT-V (also know as Mgat5) (see Figure 2) leads
to increased T-cell activation in mice, and likely increased
susceptibility to autoimmune diseases. Conversely, Partridge
et al.15 reported that upregulation of Mgat5 increases the
number of LacNAc in the N-glycans of epidermal growth
factor and transforming growth factors receptors, and
enhances cell-surface abundance of the receptors by binding
to galectin-3. This increase in cytokine receptors caused by
upregulation of Mgat5 and enhanced N-glycan processing
underlies increased cell proliferation in some malignancies.
Ohtsubo et al.20 reported that feeding a high-fat diet in
mice downregulates the expression of glycosyltransferase
Magt4a, which is one of two enzymes that synthesize the b4
N-acetylglucosamine linkage on the a3-mannose (see Figure 2).
The density of Glut-2 in b-cells is modulated by the interaction
with galectin-3. A decrease in Mgat4a reduces the lifetime of
Glut-2 on the cell surface owing to the decrease in the number
of LacNAc and in the binding of transporters to galectin-3. The
effect on the number of Glut-2 in b-cells accounts for the
induction of insulin resistance by high-fat diets.
The regulation of cell-surface expression of cytokine and
growth factor receptors and Glut-2 by interaction with
galectins described above occurs by the control of synthesis
and branching of N-glycans by glycosyltransferases in the
Golgi.14,15,20 In contrast, secreted Klotho acts from outside
the cell and targets mature glycoproteins already at the cell
surface.9 This action of Klotho represents a novel mechanism
for regulation of cell-surface glycoproteins.
Role of regulation of TRPV5 by secreted Klotho in the
overall anti-aging function of Klotho
One of the consequences of Klotho deficiency is hyperpho-
sphatemia.1 Increasing evidence indicates that the premature
aging resulting from Klotho deficiency is related to deranged
phosphate metabolism.21 Mice lacking fibroblast growth
factor-23 (FGF23), a bone-derived phosphaturic hormone,
exhibit phenotypes identical to Klotho-deficient mice,
including hyperphosphatemia, increased levels of 1,25-
vitamin D3, and premature aging.
22 Both membrane-bound
Klotho and secreted Klotho are involved in the regulation of
phosphate metabolism. Membrane-bound Klotho interacts
with FGF receptors to form high-affinity receptors for
FGF23.23 Activation of FGFR-Klotho coreceptor complexes
by FGF23 in the proximal tubule of the kidney decreases
serum phosphorus by two mechanisms. First, it reduces the
expression of Na-dependent phosphate transporters on the
luminal membrane of the proximal tubules to decrease renal
phosphate reabsorption.24 Second, it suppresses the synthesis
of 1,25-vitamin D3, which leads to decreased phosphate
absorption from the gastrointestinal tract.25 The absolute
requirement of Klotho for FGFR function explains why
Klotho deficiency and FGF23 deficiency have the same
phenotype. In addition, secreted Klotho directly inhibit
Naþ -dependent phosphate transporters by an FGF23-
independent mechanism.26 Thus, Klotho deficiency and
FGF23-deficiency cause hyperphosphatemia by increasing
intestinal phosphate absorption and increasing renal phos-
phate reabsorption.
Hyperphosphatemia can accelerate aging by several
mechanisms. High serum phosphate levels positively corre-
late with a pattern of intracellular insulin signaling and
unfavorable cell metabolism associated with aging.27 An
increase in cellular phosphate entry increases mitochondrial
membrane potential and cellular oxidative stress, which is
closely associated with cell senescence.27 In addition,
hyperphosphatemia promotes vascular calcification, which
among other things leads to organ senescence. In support of
the idea that hyperphosphatemia leads to accelerated aging,
dietary phosphate restriction prevents vascular calcification
and rescues premature aging in Klotho-deficient mice as well
as in FGF23-deficient mice.21,22,25 Thus, the effect of Klotho
to extend life is, at least in part, related to its ability to
promote renal phosphate excretion and maintain a low
phosphate balance. Low phosphate balance over a long
period of time, however, leads to bone diseases, as seen in the
conditions of acquired (tumor-induced osteomalacia) or
congenital excess of FGF23 (autosomal-dominant hypopho-
sphatemic rickets).24 The stimulation of TRPV5 and renal
Ca2þ reabsorption by secreted Klotho, as recently demon-
strated in an elegant study in animals by Alexander et al.,28
will promote positive Ca2þ balance and counteract the effect
of low phosphate balance on bone (Figure 4). Thus, the
Ca2þ -sparing effect of Klotho (absent in FGF23) prevents the
deleterious effects of low phosphate balance on bone to allow
the beneficial effects of low phosphate balance on aging-
related processes to be manifested.
REGULATION OF ROMK CHANNEL BY SECRETED KLOTHO
ROMK Kþ channel is present in the distal nephron of the
kidney and is important for Kþ secretion. In another study,
858 Kidney International (2010) 77, 855–860
min i rev iew C-L Huang: Regulation of ion channels by secreted Klotho
Cha et al.10 further reported that treatment with secreted
Klotho increases cell-surface abundance of ROMK by
removing terminal sialic acids from N-glycans of the channel.
As is for TRPV5, removal of sialic acids prevents internaliza-
tion of ROMK. Interestingly, internalization of ROMK and
TRPV5 occur via different pathways. Internalization of
ROMK occurs by clathrin-coated vesicles, whereas inter-
nalization of TRPV5 is mediated by caveolae.29,30 Thus, the
mechanism by which secreted Klotho increases cell-surface
abundance of membrane proteins by enhancing galectin–
N-glycan interaction and preventing internalization is
independent of the mechanism of protein retrieval from
the cell surface.
The physiological importance of Klotho in the regulation
of renal Kþ transport is supported by the finding that
intravenous administration of recombinant secreted Klotho
increases urinary Kþ excretion in rats.10 Angiotensin II
downregulates Klotho expression in the kidney.31 Dietary Kþ
restriction stimulates renal angiotensin II system,32 raising
the question of whether downregulation of Klotho may be
involved in Kþ conservation during dietary Kþ restriction.
REGULATION OF TRPC6 CHANNEL BY SECRETED KLOTHO
More recently, Cha et al.33 found that secreted Klotho
decreases cell-surface abundance of TRPC6. TRPC6 is a Ca2þ
channel important in the regulation of cardiac, renal
glomerular function and vascular smooth muscle cell
function related to vascular resistance and blood pressure.34
The effect of secreted Klotho on TRPC6 is opposite to that on
TRPV5 and ROMK channels and not mediated by the
sialidase activity of Klotho. Secreted Klotho appears to
decrease cell-surface expression of TRPC6 by interfering with
exocytosis of the channel stimulated by serum growth factors.
This effect resembles the inhibition of intracellular signaling
of insulin and insulin-like growth factors by Klotho.2 How
secreted Klotho antagonizes the stimulation of exocytosis of
TRPC6 by serum growth factors remains unknown. Upre-
gulation of TRPC6 is implicated in the pathogenesis of
pathological cardiac hypertrophy and renal glomerulosclero-
sis.35,36 It would be interesting to investigate whether secreted
Klotho is protective for pathological cardiac hypertrophy and
glomerular diseases caused by increased expression of
TRPC6.
SUMMARY AND FUTURE PERSPECTIVES
Accumulating evidence indicates that secreted Klotho func-
tions as a paracrine and endocrine hormone. As a paracrine
hormone, Klotho is secreted from renal tubules into urine
and regulates the surface abundance of the Ca2þ channel
TRPV5 and Kþ channel ROMK from the luminal side. As an
endocrine hormone, Klotho is released into blood circulation
and regulates the intracellular signaling by insulin and
insulin-like growth factors and the cell-surface expression
of TRPC6 present in the heart and the renal glomeruli. The
expression of Klotho decreases in chronic kidney diseases37
and presumably also in aging. A recent paper reports that
transgenic overexpression of Klotho ameliorates tubular and
glomerular injury in a mouse strain that spontaneously
develops progressive renal injury over time.38 An important
future question is whether the decrease in Klotho contributes
to the disturbances of Ca2þ and Kþ homeostasis and
impaired cardiac and renal tubular and glomerular function
associated with chronic kidney diseases and aging. Finally, it
would also be interesting to investigate in the future
whether secreted Klotho regulates cell-surface expression of
other membrane glycoproteins and whether it occurs by
the sialidase activity or by other pleiotropic effects of
secreted Klotho.
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Figure 4 |A working model depicting the potential
relationship between the effect of Klotho on calcium and
phosphate metabolism and its benefits in vascular and bone
health. Binding of FGF23 to the membrane Klotho and FGFR
coreceptor complex leads to inhibition of the synthesis of
1,25-vitamin D3 and inhibition of the expression of Na
þ -
dependent phosphate cotransporter (NaPi-2a and/or -2c) in the
apical membrane of the proximal tubule. In addition, secreted
Klotho directly inhibits NaPi-2a/2c. The overall phosphate-
lowering effects of Klotho protect against vascular calcification
(and against cellular aging; not shown here, see text for details),
but over a long period of time cause bone demineralization and
bone diseases. Secreted Klotho stimulates renal Ca2þ
reabsorption and counteracts the deleterious effect of low
phosphate balance on bone.28 The production of Klotho by the
distal tubule and the secretion into urine and blood (indicated by
dotted line) is shown. Klotho also regulates calcium homeostasis
by its effect on parathyroid hormone release from parathyroid
glands (not shown).39
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